Prebiotic firm Supergut is on a mission to enhance digestion and metabolism one intestine at a time. And with the rise of GLP-1 medicines, customers’ relationship with meals and vitamin is altering.
“It [GLP-1s] really is opening up the dialog concerning the pure approaches to attempt to regulate urge for food, regulate blood sugar management, and I’m certain you are not shocked, however a whole lot of that has to do with the intestine microbiome,” mentioned Marc Washington, founder & CEO of Supergut, a panelist at IPAWC + Probiota Americas. “I name it the ‘Ozempic period’, and it’s giving us a chance to coach extra individuals concerning the essential position of intestine well being and discovering pure methods to take care of, not simply wholesome digestion, however wholesome metabolism.”
Supergut is addressing the shortage of fiber within the eating regimen of many customers by providing prebiotic snacks, meal replacements and powders that comprise resistant starch. By closing this hole, the corporate is ready to attain a broader viewers—one thing Washington mentioned has elevated the corporate’s worth proposition.
“We have grown fairly a bit, I might say over the previous seven or eight months or so we’re up about 3-4x,” Washington mentioned. “Individuals are listening to about intestine well being on the one hand after which clearly focus so much on these GLP-1 prescription drugs after which seeing that there is a pure method…it’s actually fascinating to lots of people. And in order that’s undoubtedly helped us construct a whole lot of momentum.”
Washington described the present period as giving Supergut a chance to get again to its mission by impacting extra individuals via its public well being mission.
